About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: SHPG
- Previous Close: $181.29
- 50 Day Moving Average: $171.28
- 200 Day Moving Average: $181.07
- 52-Week Range: $297,854,000.00 - $150.06
- Trailing P/E Ratio: 145.97
- Foreward P/E Ratio: 10.43
- P/E Growth: 1.04
- Market Cap: $54.00B
- Outstanding Shares: 297,854,000
- Beta: 1.53
- Net Margins: 1.62%
- Return on Equity: 14.81%
- Return on Assets: 6.52%
Companies Related to Shire PLC:
- Debt-to-Equity Ratio: 0.70%
- Current Ratio: 1.25%
- Quick Ratio: 0.57%
What is Shire PLC's stock symbol?
Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."
How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?
Shire PLC declared a dividend on Friday, February 24th. Investors of record on Friday, March 10th will be paid a dividend of $0.771 per share on Tuesday, April 25th. The ex-dividend date of this dividend is Wednesday, March 8th. This is a boost from Shire PLC's previous dividend of $0.14.
Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?
22 brokerages have issued 12 month price targets for Shire PLC's stock. Their predictions range from $198.00 to $242.00. On average, they anticipate Shire PLC's share price to reach $227.33 in the next twelve months.
What are analysts saying about Shire PLC stock?
Here are some recent quotes from research analysts about Shire PLC stock:
- Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
According to Zacks Investment Research, "Shire is a leader in the ADHD market with drugs like Vyvanse and Intuniv. The adult ADHD space is one of the largest and fastest growing segments and a potential approval of SHP465 will further strengthen Shire’s franchise. It has expanded its presence in the gastrointestinal, neuroscience and rare disease markets through strategic acquisitions. The NPS Pharma acquisition has strengthened the company's GI franchise. Moreover, Shire’s agreement to license global rights to Pfizer’s PF-00547659 will strengthen the company’s GI pipeline further. The company updated its annual guidance with expectations of $700 million of operating cost synergies from the Baxalta acquisition (completed in Jun 2016), up from the earlier projection of $500 million. Estimates have been moving up ahead of the company’s Q3 earnings results. However, headwinds remain in the form of generic competition and unfavorable currency movements." (10/21/2016)
Leerink Swann analysts commented, "We are modestly raising our ests after SHPG beat our 1Q sales and EPS forecast driven by solid growth in ADHD and Firazyr for hereditary angioedema. Looking ahead, we expect SHPG to outperform the market driven by solid post-BXLT guidance in 2Q, several clinical catalysts in mid-2016 and a strong lifitegrast launch in dry eye. In 1Q, exceptionally strong Vyvanse sales were a critical component to the sales growth, outpacing LP by $34m, or +7% driven by strong US volume, better than expected net pricing and international expansion. Also, SHPG delivered strong Firazyr sales, beating us by $14m or +12% and strong commercial execution on a number of other rare disease products continues to validate SHPG’s tactical portfolio shift away from reformulation drugs to becoming a leading rare disease player. We remain OP & our PT is $225/ADS (up from $221). Strong top-line keyed by several flagship brands. Beyond the 1Q strength of the ADHD franchise and Firazyr, SHPG delivered inline prints on a number of important brands including Natpara (hypoparathyroidism) sales of $16m vs. our $18, Gattex (short bowel) sales of $52m (vs. our $52m) and key enzyme replacement therapy products like Replagal (Fabry) and Elaprase (Hunter’s disease). Based on the 1Q print, we’re raising our Vyvanse ests. ~2% in 2016-23, Replagal 1-4% in 2016-23 and Firazyr 2-5% 2016-19, however offsetting that is reductions to our Natpara ests of $20-65m, as our prior above cons forecasts look too aggressive." (5/2/2016)
Who owns Shire PLC stock?
Shire PLC's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (0.71%), Lone Pine Capital LLC (0.64%), Janus Capital Management LLC (0.41%), Orbimed Advisors LLC (0.40%), Marshall Wace LLP (0.35%) and DSM Capital Partners LLC (0.34%).
Who sold Shire PLC stock? Who is selling Shire PLC stock?
Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Scharf Investments LLC, FMR LLC, Federated Investors Inc. PA, Asset Management One Co. Ltd., GLG Partners LP, Renaissance Group LLC, Brown Capital Management LLC and DSM Capital Partners LLC.
Who bought Shire PLC stock? Who is buying Shire PLC stock?
Shire PLC's stock was bought by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Lone Pine Capital LLC, Senzar Asset Management LLC, Alyeska Investment Group L.P., Roystone Capital Management LP, Viking Global Investors LP, Orbimed Advisors LLC and Marshall Wace LLP.
How do I buy Shire PLC stock?
Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Shire PLC stock cost?
One share of Shire PLC stock can currently be purchased for approximately $181.29.